Summit Therapeutics Inc Stock Price, News & Analysis

Summit Therapeutics (SMMT) reported its financial results for the fourth quarter and year ending December 31, 2022. The company is progressing with its Collaboration and License Agreement with Akeso, acquiring rights to ivonescimab, a bispecific antibody for cancer treatment, for an upfront payment of $500 million. Key financials include a net loss of $78.8 million for the year, a significant decrease from $88.6 million in 2021. Summit raised $500 million in a Rights Offering to fund ongoing operations, with sufficient capital expected to cover expenses into late 2024. An earnings call is scheduled for March 9, 2023.

Summit Therapeutics has announced the successful closing of a $500 million rights offering, resulting in the sale of approximately 476.2 million shares at $1.05 per share. This offering generated net proceeds of about $499.5 million after expenses. With these funds, the company aims to support its operations, particularly focusing on ivonescimab (SMT112), into the second half of 2024. The company will host a Q4 earnings call on March 9, 2023, at 9:00 am ET.

Summit Therapeutics Inc. (NASDAQ: SMMT) is conducting a rights offering aimed at raising up to $500 million before the expiration date of March 1, 2023. Each shareholder is entitled to purchase 2.152353 shares per existing share owned, at a subscription price of either $1.05 or the volume-weighted average price leading up to the expiration date. The rights are non-transferable and will expire if not exercised. The offering is linked to a registration statement effective from February 3, 2023, and details are available in the filed prospectus with the SEC.

Summit Therapeutics Inc. (NASDAQ: SMMT) announced a rights offering scheduled for February 6, 2023, allowing current shareholders to purchase up to 476,190,476 shares of Common Stock at a price of $1.05 or the volume weighted-average price over the five days leading to the offering's expiration on March 1, 2023. If fully subscribed, the offering could generate gross proceeds of $500 million. Notably, CEO Robert W. Duggan and Co-CEO Maky Zanganeh plan to participate in the offering. A registration statement for the offering has been filed with the SEC but is yet to be effective. Investors are advised to read the final prospectus once available.

Summit Therapeutics Inc. (NASDAQ: SMMT) has finalized a definitive agreement with Akeso Inc. to in-license ivonescimab, a bispecific antibody aimed at treating non-small cell lung cancer (NSCLC). Summit will pay an upfront fee of $500 million, with $300 million already disbursed and $200 million due by March 5, 2023. Akeso retains rights for other global markets, while Summit will receive milestone payments potentially totaling $4.5 billion and royalties on net sales. Following the deal, Akeso's CEO, Dr. Michelle Xia, joins Summit's board. A rights offering is also planned for shareholders, promising $500 million in gross proceeds.

Summit Therapeutics (NASDAQ: SMMT) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 3:45 PM PST. Robert W. Duggan, Chairman and CEO, along with Dr. Maky Zanganeh, Co-CEO and President, will discuss the newly licensed bispecific antibody, ivonescimab (SMT112). Additionally, a Special Meeting of Stockholders is scheduled for January 6, 2023, at 10:00 AM PST. Summit aims to develop innovative therapies that enhance quality of life and address significant healthcare needs.

Summit Therapeutics Inc. (SMMT) has entered a definitive agreement with Akeso Inc. for a $500 million upfront payment to in-license ivonescimab, a bispecific antibody aimed at oncology treatments. This partnership allows Summit to develop and commercialize ivonescimab in the U.S., Canada, Europe, and Japan, while Akeso retains rights in other regions. The deal could reach a total value of $5 billion, contingent on regulatory milestones. Additionally, Summit is launching a rights offering to raise up to $500 million to support clinical development activities.